Last reviewed · How we verify
ACT-709478 for oral use
ACT-709478 is a selective dopamine receptor D2/D3 antagonist.
ACT-709478 is a selective dopamine receptor D2/D3 antagonist. Used for Treatment-resistant schizophrenia, Major depressive disorder.
At a glance
| Generic name | ACT-709478 for oral use |
|---|---|
| Sponsor | Idorsia Pharmaceuticals Ltd. |
| Drug class | Dopamine receptor antagonist |
| Target | D2/D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
ACT-709478 works by blocking the action of dopamine at D2/D3 receptors in the brain, which may help to reduce symptoms of psychiatric disorders such as schizophrenia and major depressive disorder.
Approved indications
- Treatment-resistant schizophrenia
- Major depressive disorder
Common side effects
- Nausea
- Dizziness
- Headache
Key clinical trials
- Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects (PHASE1)
- A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACT-709478 for oral use CI brief — competitive landscape report
- ACT-709478 for oral use updates RSS · CI watch RSS
- Idorsia Pharmaceuticals Ltd. portfolio CI